Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;20(6):1209-1217.
doi: 10.1016/j.cgh.2021.03.005. Epub 2021 Mar 10.

Treatment Candidacy for Pharmacologic Therapies for NASH

Ian A Rowe  1 , Vincent Wai-Sun Wong  2 , Rohit Loomba  3
Affiliations
Review

Treatment Candidacy for Pharmacologic Therapies for NASH

Ian A Rowe et al. Clin Gastroenterol Hepatol. 2022 Jun.

Abstract

Nonalcoholic steatohepatitis (NASH) has emerged as one of the important causes of cirrhosis and hepatocellular carcinoma, and over 50 therapeutic agents are in various phases of clinical development. Recently, obeticholic acid has achieved the interim histological endpoint of fibrosis improvement with no worsening of NASH in the phase 3 REGENERATE study, and now patients are being followed for long-term clinical outcomes. Several drugs are in Phase 3 trials with a goal to achieve conditional registration under the subpart H pathway by the United States Food and Drug Administration (FDA). It is thus timely to consider the current situation and the way ahead in the management of NASH. In this article, we review the natural history of nonalcoholic fatty liver disease, upcoming treatments for NASH and various assessments. Based on the current knowledge, we discuss what should be the target treatment population and whether noninvasive tests are ready to guide NASH treatments both for patient selection and evaluation of treatment response.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Natural history of NAFLD. Footnote: HCC, hepatocellular carcinoma; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis
Figure 2.
Figure 2.
Non-invasive tests of liver fibrosis for NAFLD. (A) Optimizing population management in NAFLD. (B) Elastography in assessing advanced fibrosis. Footnote: ARFI, acoustic radiation force impulse; ALT, alanine aminotransferase; BMI, body mass index; CHF, congestive heart failure; ELF, Enhanced Liver Fibrosis score; MRE, magnetic resonance elastography; NFS, NAFLD fibrosis score; NPV, negative predictive value; SWE, shear-wave elastography; VCTE, vibration-controlled transient elastography.
Figure 2.
Figure 2.
Non-invasive tests of liver fibrosis for NAFLD. (A) Optimizing population management in NAFLD. (B) Elastography in assessing advanced fibrosis. Footnote: ARFI, acoustic radiation force impulse; ALT, alanine aminotransferase; BMI, body mass index; CHF, congestive heart failure; ELF, Enhanced Liver Fibrosis score; MRE, magnetic resonance elastography; NFS, NAFLD fibrosis score; NPV, negative predictive value; SWE, shear-wave elastography; VCTE, vibration-controlled transient elastography.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019;69:2672–2682. - PubMed
    1. Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999–2014 e1. - PubMed
    1. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–54 e1–9; quiz e39–40. - PMC - PubMed
    1. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019;17:748–755 e3. - PubMed
    1. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398. - PubMed

Publication types

Substances